Sermorelin
5mg
A 29-amino-acid GHRH fragment used in controlled endocrine signaling studies.
Bundle & save
Strength
- Ships in 24 hours
- HPLC & endotoxin verified
- Encrypted checkout
Research details
Areas of research interest
Sermorelin is studied as a stimulator of the body's own growth hormone release. Clinical research focused on growth hormone deficiency in children, and later discussion turned to age-related GH decline in adults. It was FDA-approved in 1997 but discontinued in 2008. This research-grade material is not the formerly approved product and is not for human use.
Overview
Sermorelin is GHRH(1-29), the first 29 amino acids of the 44-amino-acid hormone growth hormone-releasing hormone. It is the shortest fragment of GHRH that keeps full activity. It acts on the pituitary GHRH receptor and preserves the body's normal feedback control of GH secretion.
Research summary
Pediatric GH deficiency. Sermorelin was used both to diagnose GH deficiency and to treat children with idiopathic GH deficiency [1]. FDA approved it under the brand name Geref in 1997, and the manufacturer discontinued it in 2008 for commercial reasons.
Adult GH decline. A 2006 review proposed sermorelin as an alternative to recombinant GH in aging adults [2]. The author argued that stimulating the pituitary preserves more of the GH axis than replacing GH directly [2].
References
- 1. Prakash A, Goa KL. BioDrugs. 1999;12(2):139–157. PMID: 18031173
- 2. Walker RF. Clin Interv Aging. 2006. PMID: 18046908
For laboratory research use only. Not for human or veterinary use. This product is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.